Merus Q3 2024 Earnings Report

Merus EPS Results

• Actual EPS: -$0.95
• Consensus EPS: -$0.90
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: N/A

Merus Revenue Results

• Actual Revenue: $11.77 million
• Expected Revenue: $9.11 million
• Beat/Miss: Beat by +$2.66 million
• YoY Revenue Growth: N/A

Merus Announcement Details

• Quarter: Q3 2024
• Date: 10/31/2024
• Time: N/A
• Conference Call Date: Thursday, October 31, 2024
• Conference Call Time: 8:00AM ET

Merus (NASDAQ:MRUS) N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.